The worst kind of cancer suddenly isn’t so scary anymore
Recent advancements in treating pancreatic cancer have sparked optimism among researchers and oncologists. A new clinical trial has shown that a KRAS-targeting pill, daraxonrasib, can significantly improve survival rates for patients with metastatic pancreatic cancer. Experts emphasize the need for continued research and early detection to further enhance treatment outcomes.
- ▪Pancreatic cancer has historically had a high mortality rate, with nearly 90 percent of patients dying within five years of diagnosis.
- ▪A recent clinical trial found that the KRAS-targeting pill daraxonrasib doubled survival rates for patients who had already undergone chemotherapy.
- ▪Experts believe that improving early detection and identifying at-risk individuals are crucial for better treatment outcomes.
Opening excerpt (first ~120 words) tap to expand
Good MedicineThe worst kind of cancer suddenly isn’t so scary anymoreScientists have made astonishing progress in treating one of the deadliest cancers.by Dylan ScottMay 21, 2026, 8:00 PM UTCShareGiftGetty Images/Science Photo LibraDylan Scott covers health for Vox, guiding readers through the emerging opportunities and challenges in improving our health. He has reported on health policy for more than 10 years, writing for Governing magazine, Talking Points Memo, and STAT before joining Vox in 2017.In a family of killer diseases, pancreatic cancer has long been one of the scariest. It could grow undetected for years, and by the time most people knew something was wrong, their prognosis was grim.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Vox.
Discussion
0 commentsMore from Vox
